Safety and efficacy of MDMA-assisted therapy for Post-Traumatic Stress Disorder in Military Veterans and First Responders: a randomised waitlist-controlled clinical trial [MMP-1]

Monash University0 个研究点目标入组 24 人开始时间: 2023年9月6日最近更新: 2024年2月27日

适应症

试验速览

暂无简介。

•*Adults with current diagnosis of PTSD.
•*Military veteran or first responder
•*Proficiency in English.
•*Availability of appropriate Support Person (relative, spouse, close friend) who can transport and provide basic support to participants following the dosing sessions.
•*Ability to discontinue certain excluded medications if deemed safe, appropriate, agreeable; if discontinuation can occur under guidance of prescribing doctor. (Note, prospective participants are not required to discontinue any medications prior to written confirmation of their enrolment into the study).
•*Agree to all study-related requirements.

•Any CNS disorders
•Current or past history of meeting DSM-5 criteria for certain excluded psychiatric indications.
•Have history of any medical condition that could make receiving a sympathomimetic drug harmful, or have any relevant cardiovascular conditions
•Diagnosis of epilepsy or previous seizures
•Major liver, kidney, thyroid abnormalities
•Insulin-dependent diabetes (unless well-managed)
•Pregnant, nursing, trying to conceive
•Taking, and inappropriate to discontinue, excluded medications, including SSRIs, SNRIs, potent metabolic inducers or inhibitors.

发起方